Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer

NCT07070128 · tracked via the Priya Life Science Brazil tracker

Sponsor

AstraZeneca

Phase

Observational

Started

2025-08-20

Last updated

2026-07-29

Condition(s) studied

Breast Neoplasms

Study summary

It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.

Eligibility

Sex

FEMALE

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * female patients, * aged 18 years or older, * identified as high genetic risk by breast surgeons, * referred to a geneticist, and * who agree to participate in the study. Exclusion Criteria: * male patients, * absence of complete information in the medical records, * patients unaware of their biological family history, and * patients who do not agree to participate in the study.

Primary outcome measure(s)

Agreement between AI tool results and genetic test results — Through study completion, an average at one year.
Implement the use of an artificial intelligence (AI)-based tool, WeConecta, to predict the genetic risk of hereditary breast cancer in women treated at a private and public institution, including analyses of the sensitivity, specificity, and positive and negative predictive values of the tool in comparison with the results of the genetic test. Hypothesis: The artificial intelligence (AI)-based tool may present a strong level of agreement regarding the indication for genetic counseling in relation to the indication of mastologists, impacting genetic testing.

Trial sites (3)

Facility	City	Region	Status
Research Site	Golania	Goiás	Withdrawn
Research Site	Porto Alegre	Rio Grande do Sul	Recruiting
Research Site	Porto Alegre	Rio Grande do Sul	Not Yet Recruiting

More AstraZeneca trials in Brazil

PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort Starting soon

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service. Recruiting

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis Active, not recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event Recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). Active, not recruiting

Other trials for the same condition

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Active, not recruiting

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Active, not recruiting

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Active, not recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07070128 on ClinicalTrials.gov ↗ ← All trials in Brazil